# Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Study · id `cardio:ct-nct01785875` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01785875](<https://clinicaltrials.gov/study/NCT01785875>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01785875

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 891 participants.

## Technical summary

Registry record NCT01785875. Allocation not applicable; no masking; primary purpose treatment. Start 2013-07-31 (actual); primary completion 2015-07-01 (actual). Results posted on 2017-03-27.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 891 participants (enrolled count; ClinicalTrials.gov record NCT01785875, source copy `cardio:ctgov-nct01785875-2019-04-10`, retrieved 2026-10-26)
- Started: 2013-07-31 (actual) (ClinicalTrials.gov record NCT01785875, source copy `cardio:ctgov-nct01785875-2019-04-10`, retrieved 2026-10-26)
- Primary completion: 2015-07-01 (actual) (ClinicalTrials.gov record NCT01785875, source copy `cardio:ctgov-nct01785875-2019-04-10`, retrieved 2026-10-26)
- Completion: 2015-07-01 (actual) (ClinicalTrials.gov record NCT01785875, source copy `cardio:ctgov-nct01785875-2019-04-10`, retrieved 2026-10-26)
- Results first posted: 2017-03-27 (ClinicalTrials.gov record NCT01785875, source copy `cardio:ctgov-nct01785875-2019-04-10`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Belgium; Canada; Czechia; France; Germany; Hungary; Israel; Italy; Netherlands; Poland; Russia; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT01785875, source copy `cardio:ctgov-nct01785875-2019-04-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01785875-2019-04-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
- Condition: Hyperparathyroidism, Secondary
- Intervention (Drug): Etelcalcetide
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism (`cardio:pubmed-30859218`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6a2951e1f911483f6da15cb42913de618d9ca7fb7276dfcb568281caed8dc218
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
